子痫前期高风险孕妇服用肠溶阿司匹林的临床效果评价

Clinical Evaluation of Enteric Aspirin in Pregnant Women at High Risk of Preeclampsia

目的:探讨肠溶阿司匹林对子痫前期(PE)高风险孕妇的预防效果。方法:收集2017年1月至2021年6月在乌鲁木齐市妇幼保健院经PE风险预测筛查为高风险并在本院建档的孕妇,按患者意愿分为干预组和非药物干预组,干预组从孕11~13^(+6)周开始给予每晚餐前服用肠溶阿司匹林。分析干预组和非药物干预组的母儿结局。结果:干预组248例,非药物干预组397例,PE高风险孕妇中PE总体发生率为33.33%(215/645),干预组PE总发生率(28.22%)低于非药物干预组(36.52%),干预组PE、重度PE、非PE发生率与非药物干预组比较,差异有统计学意义(P<0.05);干预组妊娠合并贫血的发生率(31.05%)显著低于非药物干预组(55.42%),差异有统计学意义(P<0.05)。干预组早产儿发生率(3.63%)低于非药物干预组(7.56%),差异有统计学意义(P<0.05)。结论:PE高风险孕妇从孕11~13^(+6)周开始每晚餐前服用肠溶阿司匹林对于预防PE的发生有一定效果。

Objective:To investigate the preventive effect of enteric-coated aspirin in pregnant women with high risk of preeclampsia.Methods:Pregnant women with high preeclampsia risk prediction and documented in Urumqi Maternal and Child Health Hospital from January 2017 to June 2021 were collected and divided into enteric-coated aspirin intervention group and non-intervention group according to patients′will.The intervention group was given enteric-coated aspirin before dinner from 11 to 13+6 weeks of pregnancy.Maternal and infant outcomes of intervention group and non-intervention group were analyzed.Results:There were 248 cases in the intervention group and 397 cases in the non-drug intervention group.The overall incidence of PE in pregnant women with high PE risk was 33.33%(215/645).The total incidence of PE in the intervention group(28.22%)was lower than that in the non-intervention group(36.52%).The incidence of PE,severe PE and non-PE in the intervention group was statistically significant compared with that in the non-intervention group(P<0.05).The incidence of anemia in pregnancy(31.05%)was significantly lower than that in non-intervention group(55.42%),and the difference was statistically significant(P<0.05).The incidence of premature infants in the intervention group(3.63%)was lower than that in the non-intervention group(7.56%),and the difference was statistically significant(P<0.05).Conclusions:Enteric aspirin before every dinner from 11 to 13+6 weeks of pregnancy in pregnant women at high risk of PE is effective in preventing the development of PE.